Cambios en el estadio y presentación clínica del cáncer de pulmón a lo largo de dos décadas

Leiro-Fernández, Virginia; Mouronte-Roibás, Cecilia; Ramos-Hernández, Cristina; Botana-Rial, Maribel; González-Piñeiro, Ana; García-Rodriguez, Esmeralda; Represas-Represas, Cristina; Fernández-Villar, Alberto

doi:10.1016/j.arbres.2014.03.003

Cited by 15 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding LC characteristics, the most frequent histological type was adenocarcinoma, which goes in line with other studies [5]. SCLC was significantly higher in LC + COPD patients and there was a trend, although not significant for squamous LC in this group of patients.…”

Section: Discussionsupporting

confidence: 90%

“…LC mortality is explained by the fact that most diagnoses are made in advanced stages, being able to identify tumors in localized stages only in 16–22% of cases, although new diagnostic techniques and the implementation of rapid diagnostic units are increasing the proportion of patients diagnosed with localized LC [2, 4]. In these cases, survival can reach up to 55.6% at 5 years [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background There is a relationship between Chronic Obstructive Pulmonary Disease (COPD) and the development of lung cancer (LC). The aim of this study is to analyse several blood markers and compare their concentrations in patients with only COPD and LC + COPD. Methods Case-control study with cases presenting combined LC and COPD and two control groups (patients presenting only COPD and patients presenting only LC). We also included LC patients with descriptive purposes. In both groups, peripheral blood analyses of TNF-α, IL-6, IL-8, total leukocyte, lymphocyte and neutrophil counts, neutrophil-to-lymphocyte ratio, total platelet count, mean platelet volume, platelet-to-lymphocyte ratio, alpha 1-antitripsin (A1AT), IgE, C-reactive protein, fibrinogen, cholesterol and bilirubin were performed. We developed univariate and multivariate analyses of these markers, as well as a risk score variable, and we evaluated its performance through ROC curves. Results We included 280 patients, 109 cases (LC + COPD), 83 controls (COPD) and 88 LC without COPD. No differences were observed in the distribution by sex, age, BMI, smoking, occupational exposure, lung function, GOLD stage or comorbidity. Patients with LC + COPD had significantly higher levels of neutrophils [OR 1.00 (95%CI 1.00–1.00), p = 0.03] and A1AT [OR 1.02 (95%CI 1.01–1.03), p = 0.003] and lower cholesterol levels [OR 0.98 (95%CI 0.97–0.99), p = 0.009] than COPD controls. We developed a risk score variable combining neutrophils, A1AT and cholesterol, achieving a sensitivity of 80%, a negative predictive value of 90.7% and an area under the curve of 0.78 (95%CI 0.71–0.86). Conclusions COPD patients who also have LC have higher levels of neutrophils and A1AT and lower of cholesterol. These parameters could be potentially predicting biomarkers of LC in COPD patients. Electronic supplementary material The online version of this article (10.1186/s12931-019-1155-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Adenocarcinoma was the most prevalent histological type of LC, with results similar to those of other series. 38 , 39 This could be due to several factors such as changes in the characteristics of cigarettes, changes in the classification of adenocarcinomas, the incorporation of women into smoking, and the greater number of diagnoses in asymptomatic patients, given that adenocarcinoma is a more peripheral tumor that takes longer to cause symptoms. 36…”

Section: Discussionmentioning

confidence: 99%

Influence of the type of emphysema in the relationship between COPD and lung cancer

Mouronte-Roibás

Fernández-Villar

Ruano-Raviña

et al. 2018

COPD

Self Cite

View full text Add to dashboard Cite

IntroductionThere are no studies analyzing the relationship between emphysema and lung cancer (LC). With this aim and in order to make some comparisons between different clinical variables, we carried out the present study.MethodsThis is a case–control study, patients with COPD and LC being the cases and subjects with stable COPD being the controls. Clinical and functional parameters, as well as the existence of radiological emphysema, were evaluated in a qualitative and quantitative way, using a radiological density of −950 Hounsfield units as a cutoff point in the images. The existence of several different types of emphysema (centrilobular, paraseptal, panacinar, or bullae) was analyzed, allowing patients to have more than one simultaneously. The extent to which lobes were involved was evaluated and the extension of emphysema was graduated for each type and location, following a quantitative scale. Differences between cases and controls were compared by using bivariate and multivariate analyzes with results expressed as OR and 95% CI.ResultsWe included 169 cases and 74 controls, 84% men with a FEV1 (%) of 61.7±18.5, with 90.1% non-exacerbators. Most of them (50%) were active smokers and 47.2% were ex-smokers. Emphysema was found in 80.2% of the subjects, the most frequent type being centrilobular (34.4%). The only significantly different factor was the presence of paraseptal emphysema (alone or combined; OR =2.2 [95% CI =1.1–4.3, P = 0.03]), with adenocarcinoma being significantly more frequent in paraseptal emphysema with respect to other types (67.2% vs 32.8%, P =0.03).ConclusionPatients with COPD and paraseptal emphysema could be a risk group for the development of LC, especially adenocarcinoma subtype.

show abstract

Developing PI3K Inhibitors for Respiratory Diseases

Fagone

Fruciano

Gili

et al. 2022

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Cambios en el estadio y presentación clínica del cáncer de pulmón a lo largo de dos décadas

Cited by 15 publications

References 17 publications

Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study

Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study

Influence of the type of emphysema in the relationship between COPD and lung cancer

Developing PI3K Inhibitors for Respiratory Diseases

Contact Info

Product

Resources

About